Coya Therapeutics, Inc.
A Houston-based biotech developing therapies that boost the body's regulatory T cells — the immune system's peacekeepers — to fight the inflammation behind neurodegenerative diseases like Parkinson's, Alzheimer's and ALS. Founder Dr. Howard Berman started the company in 2020 after his father's battle with dementia, teaming up with neurologist Dr. Stanley Appel. Its name echoes the earlier venture Berman co-founded, Nicoya Health.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Orin Hirschman | 13G/APassive | 3.3% | 764.7K | Jul 27, 2026 |
| AIGH Capital Management LLC | 13G/APassive | 2.7% | 631.9K | Jul 27, 2026 |
| Dr. Reddy's Laboratories, Inc. | 13GPassive | 9.7% | 2.27M | Mar 12, 2026 |
| Dr. Reddy's Laboratories SA | 13GPassive | 9.7% | 2.27M | Mar 12, 2026 |
| Dr. Reddy's Laboratories Limited | 13GPassive | 9.7% | 2.27M | Mar 12, 2026 |
| The Vanguard Group | 13G/APassive | 4.29% | 899.1K | Jan 30, 2026 |
| DME Advisors GP, L.L.C. | 13G/APassive | 9.9% | 1.65M | Feb 14, 2025 |
| EINHORN DAVID | 13G/APassive | 9.9% | 1.65M | Feb 14, 2025 |
| DME Capital Management, LP | 13G/APassive | 7.6% | 1.27M | Feb 14, 2025 |
| DME Advisors, LP | 13G/APassive | 2.3% | 383.8K | Feb 14, 2025 |